TY - JOUR
T1 - Using optical coherence tomography angiography to guide myopic choroidal neovascularization treatment
T2 - a 3-year follow-up study
AU - Ueda-Consolvo, Tomoko
AU - Shibuya, Noriko
AU - Oiwake, Toshihiko
AU - Abe, Shinya
AU - Numata, Ayaka
AU - Honda, Yuuki
AU - Yanagisawa, Shuichiro
AU - Hayashi, Atsushi
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2021/11
Y1 - 2021/11
N2 - Purpose: To report the long-term changes of the size of myopic choroidal neovascularization (mCNV) using optical coherence tomography angiography (OCTA). Methods: This was a retrospective, observational case study of eleven eyes in eleven patients with mCNV followed with OCTA for a minimum of 3 years. The flow area of mCNV on OCTA, the size of chorioretinal atrophy (CRA) and central choroidal thickness were analyzed. The relationship between the changes of mCNV size and recurrences treated with anti-vascular endothelial growth factor (VEGF) agents was also assessed. Results: Three eyes out of eleven eyes showed enlargement of the mCNV over 3 years. In two of the three eyes, the mCNV recurrences had not been treated immediately (the examination intervals were 4 months and 5 months, respectively), and we found obvious enlargement of the mCNV. In three eyes, the mCNV size decreased in 1 year and was stable thereafter without recurrences. In five eyes, mCNV size did not show remarkable changes for 3 years. In three of the five eyes, no recurrences were detected and two of the five eyes underwent prompt treatments against recurrences. Conclusion: Regular examination and prompt treatments against recurrences are critical to prevent enlargement of mCNV.[Figure not available: see fulltext.]
AB - Purpose: To report the long-term changes of the size of myopic choroidal neovascularization (mCNV) using optical coherence tomography angiography (OCTA). Methods: This was a retrospective, observational case study of eleven eyes in eleven patients with mCNV followed with OCTA for a minimum of 3 years. The flow area of mCNV on OCTA, the size of chorioretinal atrophy (CRA) and central choroidal thickness were analyzed. The relationship between the changes of mCNV size and recurrences treated with anti-vascular endothelial growth factor (VEGF) agents was also assessed. Results: Three eyes out of eleven eyes showed enlargement of the mCNV over 3 years. In two of the three eyes, the mCNV recurrences had not been treated immediately (the examination intervals were 4 months and 5 months, respectively), and we found obvious enlargement of the mCNV. In three eyes, the mCNV size decreased in 1 year and was stable thereafter without recurrences. In five eyes, mCNV size did not show remarkable changes for 3 years. In three of the five eyes, no recurrences were detected and two of the five eyes underwent prompt treatments against recurrences. Conclusion: Regular examination and prompt treatments against recurrences are critical to prevent enlargement of mCNV.[Figure not available: see fulltext.]
KW - Anti-vascular endothelial growth factor agents
KW - Chorioretinal atrophy
KW - Flow area
KW - Myopic choroidal neovascularization
KW - Optical coherence tomography angiography
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85108060688&partnerID=8YFLogxK
U2 - 10.1007/s00417-021-05270-5
DO - 10.1007/s00417-021-05270-5
M3 - 学術論文
C2 - 34142188
AN - SCOPUS:85108060688
SN - 0721-832X
VL - 259
SP - 3295
EP - 3303
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
IS - 11
ER -